News and Updates

Katie Howell was diagnosed with type 1 diabetes last year at age 25. Now, she's the first DIAGNODE-3 trial participant in NYC.

At ATTD 2025, Breakthrough T1D led sessions showcasing advancements in T1D cell therapies, early detection, and technology to improve lives.

Kelsey Voss, Ph.D., received Breakthrough T1D's Advanced Postdoctoral Fellowship Award, which helped start her lab at UVA studying T cells in type 1 diabetes.

Breakthrough T1D is funding research that supports manufactured islet cell source, survival, and protection and is also driving initiatives to unlock access to manufactured islet therapies for people with T1D.

Breakthrough T1D's new Medical Affairs unit will address the numerous challenges contributing to the slow adoption of groundbreaking T1D therapies.

Gerty Cori, Ph.D., Dorothy Crowfoot Hodgkin, FRS, and Rosalyn Yalow, Ph.D., won the Nobel Prize for diabetes discoveries.

Dr. Cassandra Bazile is a scientist at Breakthrough T1D who champions community, mentorship, and inclusion in STEM.

Marjorie Lazarre has seen the life-changing outcomes of T1D research and is confident clinical trials are the path to cures.

DIAGNODE-3 is a phase 3 clinical trial of the disease-modifying therapy Diamyd® that aims to preserve insulin-producing beta cells.

Researchers are harnessing the power of stem cells to generate functional beta cells and islets, driving us closer toward type 1 diabetes cures.